LumiraDX SARS-CoV-2 Antigen Test for Diagnosing Acute SARS-CoV-2 Infection : Critical Literature Review and Meta-Analysis
We present here a critical literature review and meta-analysis on the accuracy of the LumiraDX SARS-CoV-2 Antigen Test for diagnosing acute SARS-CoV-2 infection. An electronic search was conducted in the Scopus and Medline databases using the keywords "LumiraDX" AND "COVID-19" OR "SARS-CoV-2", without date (i.e., up to 1 February 2022) or language restrictions, for detecting clinical studies where the diagnostic accuracy of the LumiraDX SARS-CoV-2 Antigen Test was compared with reference molecular diagnostic methods. All studies where the rates of true positive, true negative, false positive and false negative cases were available for constructing a 2 × 2 table and providing pooled estimates of diagnostic sensitivity, specificity and accuracy were included in a pooled analysis. The study was conducted in accordance with the PRISMA (preferred reporting items for systematic reviews and meta-analyses) reporting checklist. Eleven studies (n = 8527 samples) could be included in our pooled analysis, while five additional documents provided diagnostic accuracy data but could not be extracted for construction of a 2 × 2 table. The pooled diagnostic sensitivity and specificity were 0.86 (95%CI, 0.84-0.88) and 0.99 (95%CI, 0.98-0.99), respectively, while the area under the summary receiver operating characteristic curve was 0.974 (95%CI, 0.965-0.983) and the agreement was 96.8% (95%CI, 96.4-97.1%), with kappa statistics of 0.87 (95%CI, 0.85-0.88). In conclusion, the diagnostic performance of the LumiraDX SARS-CoV-2 Antigen Test would allow the conclusion that it may be seen as a reliable alternative to molecular testing for the rapid preliminary screening of acute SARS-CoV-2 infections.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2022 |
---|---|
Erschienen: |
2022 |
Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
---|---|
Enthalten in: |
Diagnostics (Basel, Switzerland) - 12(2022), 4 vom: 11. Apr. |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Lippi, Giuseppe [VerfasserIn] |
---|
Links: |
---|
Themen: |
Antigen |
---|
Anmerkungen: |
Date Revised 16.07.2022 published: Electronic Citation Status PubMed-not-MEDLINE |
---|
doi: |
10.3390/diagnostics12040947 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM339831669 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM339831669 | ||
003 | DE-627 | ||
005 | 20231226003756.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231226s2022 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.3390/diagnostics12040947 |2 doi | |
028 | 5 | 2 | |a pubmed24n1132.xml |
035 | |a (DE-627)NLM339831669 | ||
035 | |a (NLM)35453996 | ||
035 | |a (PII)947 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Lippi, Giuseppe |e verfasserin |4 aut | |
245 | 1 | 0 | |a LumiraDX SARS-CoV-2 Antigen Test for Diagnosing Acute SARS-CoV-2 Infection |b Critical Literature Review and Meta-Analysis |
264 | 1 | |c 2022 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Revised 16.07.2022 | ||
500 | |a published: Electronic | ||
500 | |a Citation Status PubMed-not-MEDLINE | ||
520 | |a We present here a critical literature review and meta-analysis on the accuracy of the LumiraDX SARS-CoV-2 Antigen Test for diagnosing acute SARS-CoV-2 infection. An electronic search was conducted in the Scopus and Medline databases using the keywords "LumiraDX" AND "COVID-19" OR "SARS-CoV-2", without date (i.e., up to 1 February 2022) or language restrictions, for detecting clinical studies where the diagnostic accuracy of the LumiraDX SARS-CoV-2 Antigen Test was compared with reference molecular diagnostic methods. All studies where the rates of true positive, true negative, false positive and false negative cases were available for constructing a 2 × 2 table and providing pooled estimates of diagnostic sensitivity, specificity and accuracy were included in a pooled analysis. The study was conducted in accordance with the PRISMA (preferred reporting items for systematic reviews and meta-analyses) reporting checklist. Eleven studies (n = 8527 samples) could be included in our pooled analysis, while five additional documents provided diagnostic accuracy data but could not be extracted for construction of a 2 × 2 table. The pooled diagnostic sensitivity and specificity were 0.86 (95%CI, 0.84-0.88) and 0.99 (95%CI, 0.98-0.99), respectively, while the area under the summary receiver operating characteristic curve was 0.974 (95%CI, 0.965-0.983) and the agreement was 96.8% (95%CI, 96.4-97.1%), with kappa statistics of 0.87 (95%CI, 0.85-0.88). In conclusion, the diagnostic performance of the LumiraDX SARS-CoV-2 Antigen Test would allow the conclusion that it may be seen as a reliable alternative to molecular testing for the rapid preliminary screening of acute SARS-CoV-2 infections | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Review | |
650 | 4 | |a COVID-19 | |
650 | 4 | |a SARS-CoV-2 | |
650 | 4 | |a antigen | |
650 | 4 | |a diagnosis | |
650 | 4 | |a immunoassay | |
700 | 1 | |a Henry, Brandon M |e verfasserin |4 aut | |
700 | 1 | |a Plebani, Mario |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Diagnostics (Basel, Switzerland) |d 2011 |g 12(2022), 4 vom: 11. Apr. |w (DE-627)NLM250111136 |x 2075-4418 |7 nnns |
773 | 1 | 8 | |g volume:12 |g year:2022 |g number:4 |g day:11 |g month:04 |
856 | 4 | 0 | |u http://dx.doi.org/10.3390/diagnostics12040947 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 12 |j 2022 |e 4 |b 11 |c 04 |